



Correspondence

<https://doi.org/10.1631/jzus.B2500729>



Development and application of a novel TaqMan qPCR assay targeting the *gN* gene for genotyping pseudorabies virus

Yulan JIN^{1,2}, Xuan JI¹, Weiren DONG^{1,2}, Yanming HUANG^{1,2}, Jiyong ZHOU^{1,2}, Jinyan GU^{1,2}✉

¹The Experimental Teaching Center, College of Animal Sciences, Zhejiang University, Hangzhou 310058, China

²MOA Key Laboratory of Animal Virology, Zhejiang University Center for Veterinary Sciences, Hangzhou 310058, China

Pseudorabies virus (PRV), known as porcine herpesvirus type I, belongs to the α -herpesvirus subfamily of the herpesviridae family. Its virions are oval or round, with a genome of approximately 143 000 bp and a high guanine-cytosine (GC) content of 73% (Pomeranz et al., 2005). While swine are the natural host and the virus has caused significant economic loss to the pig industry, PRV can infect other mammals, causing acute infectious diseases characterized by neurological symptoms (He et al., 2019; Cheng et al., 2020). Young pigs are more susceptible to PRV and the infection in piglets is nearly 100% fatal, whereas adult pigs exhibit reproductive disorders such as abortion, stillbirths, and reduced fertility, ultimately decreasing farm productivity (Zuckermann, 2000). Due to its global impact, PRV is classified as a Class B infectious disease by the World Organization for Animal Health (WOAH).

Widespread use of the attenuated Bartha-K61 vaccine effectively curbed PRV outbreaks for years (Delva et al., 2020; Zheng et al., 2022). However, PRV outbreaks have re-emerged in China even in Bartha-K61-vaccinated herds since 2011 (Tan et al., 2021). The emerging strains, designated PRV genotype II, exhibit significantly higher virulence than the classic genotype I strains (Zhai et al., 2019). Existing vaccines for genotype I offer limited cross-protection against PRV genotype II (An et al., 2013); consequently, the development of a vaccine specifically

targeting PRV genotype II represents a milestone for controlling the ongoing epidemic (Jin et al., 2022). An effective control strategy, however, requires an integrated approach that combines effective vaccination with rapid, highly sensitive diagnostic methods capable of differentiating between PRV genotypes.

Common methods for detecting PRV include virus isolation and cultivation, polymerase chain reaction (PCR), and immunological assays (Morenkov et al., 1997; Wu et al., 2023). Among these, PCR is widely preferred due to its rapidity, high sensitivity, and strong specificity (Tu et al., 2022). It enables high-throughput screening of a large panel of samples and is suitable for live detection, making it ideal for clinical diagnosis (Ding et al., 2024). Of the various PCR-based methods, the TaqMan assay offers superior specificity compared to SYBR Green, establishing it as a reliable technique for clinical applications. Current PRV genotyping predominantly targets envelope glycoprotein genes such as glycoprotein B (*gB*), *gC*, *gD*, and *gE* (Song et al., 2017). However, whether other envelope glycoprotein genes can serve as effective genotyping markers remains unclear. An ideal genotyping target requires two key features: inter-genotype variability to enable clear differentiation and strong intra-genotype conservation to ensure reliable detection. In this study, analysis of PRV genomic DNA led to the identification of the *gN* gene and, for the first time, the discovery of conserved, genotype-specific signature sequences within it. We aim to utilize these sequences to develop a multiplex TaqMan probe-based real-time quantitative PCR (TaqMan qPCR) assay for rapid and accurate genotyping of PRV.

Based on comparative analysis of complete PRV genotypes I and II genome sequences using SnapGene, we identified several conserved regions within the *gN*

✉ Jinyan GU, gujinyan@zju.edu.cn

Jinyan GU, <https://orcid.org/0000-0002-9763-9569>

Yulan JIN, <https://orcid.org/0000-0002-7752-5062>

Received Nov. 13, 2025; Revision accepted Feb. 24, 2026;
Crosschecked July 10, 2026; Published online Aug. 6, 2026

© Zhejiang University Press 2026

gene (Figs. 1a and 1b). Specifically, positions 105–123 and 400–418, which are conserved across both genotypes, were selected as the upstream and downstream primers, respectively. The region positions 195–211, also conserved in both genotypes, was chosen for the universal probe. For genotype-specific detection, positions 321–340 of the *gN* gene, highly conserved and unique to PRV genotype I, were selected as the PRV genotype I probe. Similarly, positions 325–340, which are conserved specifically in PRV genotype II, were selected for designing the PRV genotype II probe. The detailed positions and sequences are shown in Fig. 1a.

The *gN* gene sequences of PRV genotypes I (PRV-Bartha-K61) and II (PRV-DX) were amplified with PCR using their respective genomic DNAs as

templates. The amplified products were blunt-end ligated into the pUC-19 vector using the pClone007 Versatile Simple Vector Kit (TSV-007VS, Beijing Tsingke Biotech Co., Ltd., Beijing, China), and then transformed into *Escherichia coli* DH5 α competent cells. The positive strains were screened and the plasmids were extracted and purified, yielding the recombinant plasmids pUC-PRV-Bartha-K61 (pUC-BT) and pUC-PRV-DX (pUC-DX).

Using serial dilutions (10 to 1 $\times$ 10⁶ copies/ μ L) of the standard plasmids pUC-BT and pUC-DX as templates, we generated standard curves for PRV genotypes I and II by plotting the cycle threshold (C_t) values against the logarithms of the plasmid copy numbers (Figs. 1c and 1d). The standard curve of PRV genotype I was $Y=-3.561X+41.056$, with a coefficient of




Fig. 1 Diagram of the primers or probes of the *gN* gene for genotyping of PRV and standard curve or specificity of the TaqMan qPCR assay. (a) Primers and positions of the *gN* gene for genotyping of PRV. (b) Sequence alignment of *gN* genes of PRV genotypes I and II. (c, d) Standard curves of the TaqMan qPCR assay of PRV genotypes I (c) and II (d). (e) Specificity of the TaqMan qPCR assay. *gN*: glycoprotein N; F: forward; R: reverse; Cy5: cyanine 5; BHQ2/3: black hole quencher 2/3; FAM: 6-carboxyfluorescein; MGB: minor groove binder; PRV: pseudorabies virus; C_t : cycle threshold; PCV2/3/4: porcine circovirus type 2/3/4; PEDV: porcine epidemic diarrhea virus; PRRSV: porcine reproductive and respiratory syndrome virus; PDCoV: porcine deltacoronavirus; CSFV: classical swine fever virus; RFU: relative fluorescence unit.

determination (R^2) of 0.9997. For PRV genotype II, the standard curve was $Y = -3.733X + 43.677$, with $R^2 = 0.9998$. These results indicated a good linear relationship across the dilution range (10 to 1×10^6 copies/ μ L). The minimum detection limit of the established method was determined to be 20 copies/ μ L.

The analytical sensitivity of the established triplex-probe assay was compared to that of the single-probe format under identical reaction conditions. The TaqMan qPCR assay contained 10.0 μ L of $2 \times$ AceQ qPCR probe master mix, 2.0 μ L of templates, 0.9 μ L each of upstream and downstream primers (10 μ mol/L), and 0.4 μ L of each probe (10 μ mol/L), and ddH₂O was used to make up to 20.0 μ L. The TaqMan-based PCR conditions were as follows: pre-denaturation at 95 °C for 30 s, and 40 amplification cycles of 95 °C for 10 s and 60 °C for 30 s. Both assays achieved a minimum detection limit of 20 copies/ μ L, demonstrating that the high sensitivity of the detection system was maintained despite increased probe multiplexing.

The specificity of the triplex qPCR assay was verified by its ability to detect PRV genotypes I and II exclusively in their respective channels. No cross-reactivity was observed with other swine pathogens, such as porcine deltacoronavirus (PDCoV), classical swine fever virus (CSFV), porcine reproductive and respiratory syndrome virus (PRRSV), porcine epidemic diarrhea virus (PEDV), porcine circovirus type 2 (PCV2), or plasmids containing full-length PCV3 and PCV4 genomes (Fig. 1e). These results demonstrated that the established method effectively differentiated PRV genotypes I and II with high specificity.

To evaluate repeatability, we tested tenfold serial dilutions of the standard plasmids (10 to 1×10^6 copies/ μ L) under the established conditions. Intra-assay variability was assessed by testing each dilution in triplicate within a single run, while inter-assay variability was determined by repeating the experiment on three separate days. As shown in Table S1, the inter-assay coefficients of variation (CVs) ranged from 0.94% to 1.62% for PRV genotype I, and from 1.80% to 2.74% for PRV genotype II. Intra-assay CVs for both genotypes were below 2% (Table S2). Thus, the established triplex qPCR assay exhibited high repeatability and stability for the detection and differentiation of PRV genotypes.

Genomic DNA was extracted from 54 experimental animal samples and subjected to detection using the established triplex TaqMan qPCR assay.

PRV-DX and PRV-Bartha-K61 were used as positive controls, and ddH₂O as the negative control. The assay identified 29 positive samples, yielding a positive rate of 53.70%; this was substantially higher than the 25.93% positive rate obtained using the conventional PCR method recommended by the national standard “Diagnostic Method for Pseudorabies, GB/T 18641-2018” (State Administration for Market Regulation and Standardization Administration of China, 2018). Notably, all positive samples detected by the multiplex qPCR assay were identified as PRV genotype II. This genotyping result was confirmed by sequencing and phylogenetic analysis, which classified all positive samples as PRV genotype II. These findings demonstrated that, compared to conventional PCR, the established multiplex TaqMan qPCR assay not only exhibited superior sensitivity for detecting PRV-positive clinical samples, but also enabled simultaneous genotype identification, highlighting its practical value for clinical diagnosis and epidemiological surveillance. It should be noted that although virulence may vary among different PRV strains within the same genotype, sequence analysis of the *gN* gene revealed only two distinct sequence types corresponding to genotypes I and II. Nevertheless, further validation using a broader panel of clinically representative PRV strains is necessary to further substantiate the assay’s generalizability and reliability for genotyping applications.

In this study, we developed a triplex TaqMan qPCR assay for the simultaneous detection and genotyping of PRV, offering high specificity, sensitivity, and stability, and user-friendly operation. A key advantage of this method is its capacity to perform PRV identification and genotype discrimination in a single reaction, substantially improving detection efficiency. Notably, this detection assay represents the first application of the *gN* gene for PRV genotyping, which addresses limitations associated with conventional genetic targets. Furthermore, the use of a single pair of specific primers simplifies the reaction system, reduces primer consumption by two-thirds, and effectively minimizes the risk of primer mismatches and non-specific amplification. Collectively, these features position the proposed method as a practical and effective tool for PRV genotyping in clinical settings. We expect that it will provide valuable support for PRV epidemiological surveillance and contribute to efforts aimed at eradicating persistently infected swine populations.

Data availability statement

The data used to support the findings of this study are included within the article and its supplementary materials. No additional datasets were generated or analysed during the current study.

Acknowledgments

This work was supported by the Hangzhou Chengxi Sci-Tech Innovation Corridor Management Committee (No. B231220.0005-46) and the National Key R&D Program of China (No. 2022YFD1800804). The authors thank Mr. Weidong ZENG of the Experimental Teaching Center, College of Animal Sciences, Zhejiang University, Hangzhou, China for facility support.

Author contributions

Yulan JIN, Xuan JI, and Weiren DONG performed the experimental research and data analysis, and wrote and edited the manuscript. Yanming HUANG contributed to the software analysis. Jiyong ZHOU and Jinyan GU contributed to the study conceptualization, supervision, and funding acquisition, and reviewed and edited the manuscript. All authors have read and approved the final manuscript, and therefore, have full access to all the data in the study and take responsibility for the integrity and security of the data.

Compliance with ethics guidelines

Yulan JIN, Xuan JI, Weiren DONG, Yanming HUANG, Jiyong ZHOU, and Jinyan GU declared that they have no conflicts of interest.

The collection and use of experimental animal samples in this study were approved by the Laboratory Animal Welfare and Ethics Review Committee, Zhejiang University (No. ZJU20240676). All procedures followed were in accordance with the experimental animal ethics guidelines of Zhejiang University.

Declaration on the use of generative AI tools

We declare that no generative AI tools were used in the creation of this manuscript. All content, analysis, and writing were performed solely by the authors.

References

- An TQ, Peng JM, Tian ZJ, et al., 2013. Pseudorabies virus variant in Bartha-K61-vaccinated pigs, China, 2012. *Emerg Infect Dis*, 19(11):1749-1755. <https://doi.org/10.3201/eid1911.130177>
- Cheng ZL, Kong ZJ, Liu P, et al., 2020. Natural infection of a variant pseudorabies virus leads to bovine death in China. *Transbound Emerg Dis*, 67(2):518-522. <https://doi.org/10.1111/tbed.13427>
- Delva JL, Nauwynck HJ, Mettenleiter TC, et al., 2020. The attenuated pseudorabies virus vaccine strain Bartha K61: a brief review on the knowledge gathered during 60 years of research. *Pathogens*, 9(11):897. <https://doi.org/10.3390/pathogens9110897>
- Ding SX, Shen TR, Feng ZX, et al., 2024. Development of a highly sensitive TaqMan method based on multi-probe strategy: its application in ASFV detection. *Biol Methods Protoc*, 9(1):bpae011. <https://doi.org/10.1093/biomethods/bpae011>
- He WT, Auclert LZ, Zhai XF, et al., 2019. Interspecies transmission, genetic diversity, and evolutionary dynamics of pseudorabies virus. *J Infect Dis*, 219(11):1705-1715. <https://doi.org/10.1093/infdis/jiy731>
- Jin YL, Yin D, Xing G, et al., 2022. The inactivated gE/TK gene-deleted vaccine against pseudorabies virus type II confers effective protection in mice and pigs. *Front Microbiol*, 13:943707. <https://doi.org/10.3389/fmicb.2022.943707>
- Morenkov OS, Sobko YA, Panchenko OA, 1997. Glycoprotein gE blocking ELISAs to differentiate between Aujeszky's disease-vaccinated and infected animals. *J Virol Methods*, 65(1):83-94. [https://doi.org/10.1016/s0166-0934\(96\)02171-4](https://doi.org/10.1016/s0166-0934(96)02171-4)
- Pomeranz LE, Reynolds AE, Hengartner CJ, 2005. Molecular biology of pseudorabies virus: impact on neurovirology and veterinary medicine. *Microbiol Mol Biol Rev*, 69(3):462-500. <https://doi.org/10.1128/MMBR.69.3.462-500.2005>
- Song CL, Gao LB, Bai WB, et al., 2017. Molecular epidemiology of pseudorabies virus in Yunnan and the sequence analysis of its gD gene. *Virus Genes*, 53(3):392-399. <https://doi.org/10.1007/s11262-017-1429-z>
- State Administration for Market Regulation, Standardization Administration of China, 2018. Diagnostic Method for Pseudorabies, GB/T 18641-2018. Standards Press of China, Beijing, China.
- Tan L, Yao J, Yang YD, et al., 2021. Current status and challenge of pseudorabies virus infection in China. *Virol Sin*, 36(4):588-607. <https://doi.org/10.1007/s12250-020-00340-0>
- Tu F, Zhang YN, Xu SK, et al., 2022. Detection of pseudorabies virus with a real-time recombinase-aided amplification assay. *Transbound Emerg Dis*, 69(4):2266-2274. <https://doi.org/10.1111/tbed.14241>
- Wu XM, Chen RJ, Chen QY, et al., 2023. Establishment of an indirect ELISA method for antibody detection of porcine pseudorabies by recombinant gB, gC, and gD proteins. *J Med Virol*, 95(1):e28228. <https://doi.org/10.1002/jmv.28228>
- Zhai XF, Zhao W, Li KM, et al., 2019. Genome characteristics and evolution of pseudorabies virus strains in Eastern China from 2017 to 2019. *Virol Sin*, 34(6):601-609. <https://doi.org/10.1007/s12250-019-00140-1>
- Zheng HH, Fu PF, Chen HY, et al., 2022. Pseudorabies virus: from pathogenesis to prevention strategies. *Viruses*, 14(8):1638. <https://doi.org/10.3390/v14081638>
- Zuckermann FA, 2000. Aujeszky's disease virus: opportunities and challenges. *Vet Res*, 31(1):121-131. <https://doi.org/10.1051/vetres:2000111>

Supplementary information

Tables S1 and S2